Global Custom Market Research Reports Provider Company

phone

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

  • Published Date: 12 Jun 2018
  • Number of Pages: 56
  • Category: Pharmaceuticals
  • Country: Global
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushings disease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
Diurnal Group Plc
Ipsen SA
Novartis AG
Strongbridge Biopharma plc
Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit POMC for Cushings Syndrome and Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushings Disease, a Serious Endocrine Disorder
Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases
Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Societys 97th Annual Meeting & Expo
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial
Jul 30, 2012: Cortendos NormoCort Receives Orphan Drug Designation from EMA to Treat Cushings Syndrome
Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushings Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2018
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018, provides

View Report

Pituitary ACTH Hypersecretion (Cushings Disease) - Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Pituitary ACTH Hypersecretion (Cushings

View Report

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2017, provides

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports